

**UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 29 FEBRUARY 2020  
FOR  
SUMA MEDICS LTD**

**CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 29 FEBRUARY 2020**

---

	<b>Page</b>
<b>Company Information</b>	1
<b>Balance Sheet</b>	2
<b>Notes to the Financial Statements</b>	4

**DIRECTORS:**

Doctor A E Elmubarak  
Mrs S A Elmubarak

**REGISTERED OFFICE:**

Unit 2.02  
High Weald House  
Glovers End  
Bexhill  
East Sussex  
TN39 5ES

**REGISTERED NUMBER:**

04589261 (England and Wales)

**ACCOUNTANTS:**

Acuity Professional Partnership LLP  
Unit 2.02  
High Weald House  
Glovers End  
Bexhill  
East Sussex  
TN39 5ES

**BALANCE SHEET**  
**29 FEBRUARY 2020**

		<b>2020</b>		<b>2019</b>	
	<b>Notes</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
<b>FIXED ASSETS</b>					
Tangible assets	4		<b>843</b>		1,124
Investment property	5		<u>-</u>		<u>273,044</u>
			<b>843</b>		<u>274,168</u>
<b>CREDITORS</b>					
Amounts falling due within one year	6	<u><b>4,389</b></u>		<u>55,349</u>	
<b>NET CURRENT LIABILITIES</b>			<u><b>(4,389)</b></u>		<u>(55,349)</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			<u><b>(3,546)</b></u>		<u><b>218,819</b></u>
<b>CAPITAL AND RESERVES</b>					
Called up share capital			<b>20</b>		20
Retained earnings			<u><b>(3,566)</b></u>		<u>218,799</u>
<b>SHAREHOLDERS' FUNDS</b>			<u><b>(3,546)</b></u>		<u><b>218,819</b></u>

The notes form part of these financial statements

**BALANCE SHEET - continued**  
**29 FEBRUARY 2020**

---

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 29 February 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 29 February 2020 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 November 2020 and were signed on its behalf by:

Doctor A E Elmubarak - Director

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 29 FEBRUARY 2020**


---

**1. STATUTORY INFORMATION**

Suma Medics Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

**2. ACCOUNTING POLICIES**
**BASIS OF PREPARING THE FINANCIAL STATEMENTS**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**TANGIBLE FIXED ASSETS**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery            - 25% on reducing balance  
Computer equipment            - 33% on cost

**3. EMPLOYEES AND DIRECTORS**

The average number of employees during the year was 2 (2019 - 2 ) .

**4. TANGIBLE FIXED ASSETS**

	<b>Plant and machinery £</b>	<b>Fixtures and fittings £</b>	<b>Computer equipment £</b>	<b>Totals £</b>
<b>Cost</b>				
At 1 March 2019 and 29 February 2020	<u><b>1,819</b></u>	<u><b>8,000</b></u>	<u><b>3,603</b></u>	<u><b>13,422</b></u>
<b>Depreciation</b>				
At 1 March 2019	<b>1,763</b>	<b>6,932</b>	<b>3,603</b>	<b>12,298</b>
Charge for year	<u><b>14</b></u>	<u><b>267</b></u>	<u><b>-</b></u>	<u><b>281</b></u>
At 29 February 2020	<u><b>1,777</b></u>	<u><b>7,199</b></u>	<u><b>3,603</b></u>	<u><b>12,579</b></u>
<b>Net book value</b>				
At 29 February 2020	<u><b>42</b></u>	<u><b>801</b></u>	<u><b>-</b></u>	<u><b>843</b></u>
At 28 February 2019	<u><b>56</b></u>	<u><b>1,068</b></u>	<u><b>-</b></u>	<u><b>1,124</b></u>

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 29 FEBRUARY 2020**

---

**5. INVESTMENT PROPERTY**

	<b>Total £</b>
<b>Fair value</b>	
At 1 March 2019	<b>273,044</b>
Disposals	<b>(273,044)</b>
At 29 February 2020	<b>-</b>
<b>Net book value</b>	
At 29 February 2020	<b>-</b>
At 28 February 2019	<b>273,044</b>

**6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2020 £</b>	<b>2019 £</b>
Directors' current accounts	<b>3,308</b>	54,808
Accruals and deferred income	<b>1,081</b>	541
	<b><u>4,389</u></b>	<b><u>55,349</u></b>